Physician profile
Scott R Roman
NPI 1952364192
$117,653.82
in general payments reported to CMS, 2019-2025
16 companies · $107K in 2025
The $107K reported for 2025 was more than what 99% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.16 · 2020: $31.86 · 2021: $63.40 · 2022: $3,625 · 2023: $4,015 · 2024: $2,785 · 2025: $107K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $113K · Food and Beverage: $482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $113,437.77 |
| Food and Beverage | $482.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arrowhead De LLC | $106,945.05 | 2025 | Arrow-Lok Digital Fusion System |
| Fuse Medical, INC. | $10,027.08 | 2022-2025 | Orbitum Staple System |
| Medtronic, INC. | $287.06 | 2022-2024 | Closurefast, Intellis Adaptivestim |
| Nevro Corp. | $67.83 | 2022-2024 | Senza |
| Amgen INC. | $49.76 | 2024 | Krystexxa |
| Horizon Therapeutics Plc | $44.33 | 2021-2023 | Krystexxa |
| Paratek Pharmaceuticals, INC. | $41.71 | 2021-2025 | Nuzyra |
| Depuy Synthes Sales INC. | $40.20 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $38.26 | 2023 | Seglentis |
| Triad Life Sciences INC. | $23.01 | 2022 | |
| Orthofix Medical, INC. | $19.54 | 2020 | |
| Mimedx Group, INC. | $16.11 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $15.39 | 2025 | |
| Merck Sharp & Dohme LLC | $13.16 | 2019 | |
| Stryker Corporation | $13.01 | 2023 | Variax |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aroa Biosurgery Incorporated | $12.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$150,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Roman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.